EUA Submitted for Moderna COVID-19 Vaccine Amendment for Fourth Dose
The FDA approved the Moderna vaccine as a 2-dose primary series for persons 18 years of age and older earlier this year.
(Adobe Stock)
This article was originally published in ContagionLive.com.
Moderna announced yesterday it has submitted its amended application for an Emergency Use Authorization to the Food and Drug Administration (FDA) to include its Spikvax COVID-19 vaccine for a fourth booster dose for people 18 years of age and older who have received an initial booster of any of the authorized or approved COVID-19 vaccines.
This development comes shortly after Pfizer applied for an EUA for a fourth dose of its COVID-19 vaccine.
As concerns of the BA.2 COVID-19 sub-variant, called “Deltacron” or “Stealth Omicron,” which appears to be the most contagious strain thus far, and some medical experts calling it as contagious as measles, as well as cases growing in China and Europe, there have been calls for proactive steps such as offering another booster shot to protect people.
American public health officials are watching this variant, but have not changed guidance on mask-wearing or other prevention measures for the moment.
Earlier this year, the FDA approved the Moderna vaccine as a 2-dose primary series for persons 18 years of age and older.
“Our COVID-19 vaccine has been administered to hundreds of millions of people around the world, protecting people from COVID-19 infection, hospitalization and death,” Moderna CEO Stéphane Bancel, said at the time. “The totality of real-world data and the full BLA for Spikevax in the United States reaffirms the importance of vaccination against this virus.”
Moderna's vaccine has received approval by regulators in more than 70 countries, including Canada, Japan, the European Union, the UK, Israel, according to Moderna.
In late January, the company announced it had begun its phase 2 clinical trial extension for its Omicron-specific booster (mRNA-1273.529) vaccine candidate. Moderna said it was an extension of an earlier study that will evaluate the immunogenicity, safety, and reactogenicity of mRNA-1273.529 as a single booster dose in adults aged 18 years and older.
Antibiotic Stewardship in Long-Term Care: Leveraging McGeer and Loeb Criteria for Better Outcomes
February 28th 2025Antibiotic stewardship in long-term care facilities relies on McGeer and Loeb criteria to guide infection surveillance and appropriate prescribing, ensuring better outcomes for residents and reducing resistance.
Oral Parasites and Periodontal Disease: The Hidden Threat to Dental Health
February 28th 2025Entamoeba gingivalis and Trichomonas tenax are protozoan parasites linked to periodontal disease. Emerging research highlights their role in oral inflammation, tissue destruction, and worsening gum disease.
Rare Disease Month: Nipah Virus—It Is From Bats!
February 28th 2025For Rare Disease Month, Rebecca Leach, MPH, BSN, RN, CIC, writes on Nipah virus, a rare but deadly zoonotic disease that poses a significant public health threat. With high mutation potential and no cure, prevention and awareness are critical.
Beyond Civil Rights: Black Trailblazers in Medicine and Infection Prevention
February 28th 2025Black History Month should celebrate pioneers like Drs William Hinton, Daniel Hale Williams, and Charles Drew, whose medical breakthroughs revolutionized infection prevention, surgery, and blood preservation.
The Latest on CLABSIs and CAUTIs: Evidence-Based Approaches for Infection Prevention
February 27th 2025Health care–associated infections like CLABSIs and CAUTIs threaten patient safety. Learn evidence-based strategies, new technologies, and prevention protocols to reduce these infections and improve outcomes.
